Acura Pharmaceuticals
The topic of this article may not meet Wikipedia's notability guidelines for companies and organizations. (February 2014) |
Company type | Public |
---|---|
Nasdaq: ACUR | |
Industry | Pharmaceutical industry |
Founded | 1935[1]: 3 |
Headquarters | Palatine, Illinois |
Products | Pharmaceuticals |
Revenue | US$ .75 million (2015)[2] |
Website | acurapharm |
Acura Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of deterrents to medication abuse and misuse.[3] As of 2012[update], the company had several opioid products under development, which would use "Aversion Technology".[4] As of 2014[update], it was a publicly traded company, listed on NASDAQ under the symbol "ACUR".
History
[edit]In 2013, the Company settled Oxecta patent litigation with Impax Laboratories (IPXL) and Par Pharmaceutical.[5]
License agreements
The company has an agreement to license, develop and commercialize opioid analgesic products with King Pharmaceuticals.[6]
Product adoptions
In 2013, multiple retailers – including Kroger and Fruth Pharmacy – stocked Acura's product Nexafed.[7][8]
References
[edit]- ^ "ACURA PHARMACEUTICALS, INC" (PDF). EDGAR Online. Form 10-K, 1996. Acura Pharmaceuticals. March 31, 1997. Retrieved February 15, 2014.[permanent dead link ]
- ^ "Acura Pharmaceuticals Financial Statements". United States Securities and Exchange Commission.
- ^ "Acura Pharmaceuticals Announces Second Quarter 2020 Financial Results". AP NEWS. 2020-08-14. Retrieved 2021-07-22.
- ^ "Acura Pharmaceuticals, Inc". Google Finance. 266634. Archived from the original on 10 May 2014. Retrieved February 15, 2014.
{{cite web}}
: CS1 maint: bot: original URL status unknown (link) - ^ "Acura Pharmaceuticals Inc Announces Settlement of Oxecta Patent Litigation With Par Pharmaceutical and Impax Laboratories Inc". Reuters. Reuters. October 9, 2013. Archived from the original on February 15, 2014.
- ^ "ACURA PHARMACEUTICALS INC (ACUR) Company Profile & Facts - Yahoo Finance".
- ^ Olsavsky, Rebecca (February 4, 2014). "Kroger stocks meth-resistant drug". Herald-Star. Archived from the original on February 15, 2014. Retrieved February 15, 2014.
- ^ "New Pseudoephedrine Drug Could Hop Back Over the Counter". PharmExec. 11 December 2012. Retrieved 2021-07-22.